Table 4.
Inhaler use according to underlying airway disease (bronchiectasis)
| Airway disease | SAMA/SABA | LAMA/LABA | +ICS |
| Bronchiectasis specific patients | |||
| Bronchiectasis (radiology or EMR) (n=142) | 22/142 (16%) | 12/142 (8%) | 108/142 (76%) |
| Bronchiectasis (radiology or EMR) with no asthma/BDR (n=124) | 19/124 (15%) | 11/124 (9%) | 94/124 (76%) |
| Bronchiectasis (radiology or EMR) with no asthma/BDR and no airway obstruction (n=31) | 5/31 (16%) | 3/31 (10%) | 23/31 (74%) |
| Bronchiectasis (radiology or EMR) with no asthma/BDR and no airway obstruction and no COPD (radiology) (n=29) | 5/29 (17%) | 3/29 (10%) | 21/29 (72%) |
| Bronchiectasis (radiology or EMR) with no asthma/BDR and no airway obstruction and no COPD (any) (n=5) | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Total cohort of patients | |||
| Asthma (EMR or BDR on PFT) (n=97) | 11/97 (12%) | 8/97 (8%) | 78/97 (80%) |
| COPD (radiology or EMR) (n=313) | 36/313 (12%) | 28/313 (9%) | 249/313 (80%) |
BDR, bronchodilator response; COPD, chronic obstructive pulmonary disease; EMR, electronic medical record; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β-agonists; LAMA, long-acting muscarinic antagonists; PFT, pulmonary function test; SABA, short-acting bronchodilator; SAMA, short-acting muscarinic antagonists.